Literature DB >> 16894398

Tacrolimus: focusing on atopic dermatitis.

Christie L Carroll1, Alan B Fleischer.   

Abstract

Tacrolimus ointment is an effective treatment for atopic dermatitis. As a calcineurin inhibitor, it works through the FK-binding protein, inhibiting calcineurin and preventing dephosphorylation of nuclear factor of activated T cells (NFAT). Systemic absorption from the drug is minimal, allowing a favorable safety profile. In head-to-head clinical trials with pimecrolimus, tacrolimus proved to be a more effective treatment. Tacrolimus ointment has also been compared to standard topical cortico-steroid treatments and is equally effective if not superior to several topical steroids. Overall, tacrolimus ointment is a safe and effective treatment for atopic dermatitis and can be used as an adjunctive treatment to standard management with topical corticosteroids. (c) 2006 Prous Science. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16894398     DOI: 10.1358/dot.2006.42.7.1003316

Source DB:  PubMed          Journal:  Drugs Today (Barc)        ISSN: 1699-3993            Impact factor:   2.245


  4 in total

Review 1.  Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice.

Authors:  Elaine C Siegfried; Jennifer C Jaworski; Adelaide A Hebert
Journal:  Am J Clin Dermatol       Date:  2013-06       Impact factor: 7.403

2.  Preparation and in vitro evaluation of tacrolimus-loaded ethosomes.

Authors:  Guiling Li; Chao Fan; Xinru Li; Yating Fan; Xiaoning Wang; Mei Li; Yan Liu
Journal:  ScientificWorldJournal       Date:  2012-05-02

3.  Forsythia suspensa Suppresses House Dust Mite Extract-Induced Atopic Dermatitis in NC/Nga Mice.

Authors:  Yoon-Young Sung; Taesook Yoon; Seol Jang; Ho Kyoung Kim
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

4.  Rcan1 negatively regulates Fc epsilonRI-mediated signaling and mast cell function.

Authors:  Yong Jun Yang; Wei Chen; Alexander Edgar; Bo Li; Jeffery D Molkentin; Jason N Berman; Tong-Jun Lin
Journal:  J Exp Med       Date:  2009-01-05       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.